Medicine and Dentistry
Bladder Cancer
100%
In Vitro
50%
Arm
50%
Mantle Cell Lymphoma
50%
Mononuclear Cell
50%
Lenalidomide
50%
Rituximab
50%
Peripheral T-Cell Lymphoma
50%
Autologous Stem Cell Transplantation
50%
Survivin
50%
Urinary System
50%
Dendritic Cell
50%
Ibrutinib
50%
Cisplatin
50%
Cancer Recurrence
50%
Cytotechnology
40%
Neoplasm
36%
High Dose Chemotherapy
31%
Immunohistochemistry
25%
Hazard Ratio
25%
Sensitivity and Specificity
20%
Cystoscopy
20%
Urine Sampling
20%
Tumor Recurrence
20%
Dose Densification
18%
Visceral Metastasis
16%
Survival Time
16%
Malignant Neoplasm
16%
Disease
14%
Monocyte
12%
Anaplastic Lymphoma Kinase
12%
Anaplastic Large Cell Lymphoma
12%
Progression Free Survival
12%
Etoposide
12%
Diagnosis
10%
Recurrent Disease
10%
Biological Marker
10%
Biopsy
10%
Bladder
10%
Reverse Transcription Polymerase Chain Reaction
10%
Odds Ratio
8%
Multivariate Analysis
8%
Survival Rate
8%
Transitional Cell Carcinoma
8%
Prognostic Factor
8%
Urothelium
8%
Neutropenia
8%
Skin Toxicity
8%
Treatment Duration
8%
Oncology
8%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
50%
Survivin
50%
Ibrutinib
50%
Peripheral T Cell Lymphoma
50%
Pixantrone
50%
Nonhodgkin Lymphoma
42%
High Dose Chemotherapy
31%
Anthracycline
21%
Rituximab
21%
Doxorubicin
20%
Prednisone
20%
Etoposide
19%
Cardiotoxicity
14%
Vincristine
13%
Cyclophosphamide
13%
Progression Free Survival
12%
Anaplastic Lymphoma Kinase
12%
Anaplastic Large Cell Lymphoma
12%
Remission
12%
Cisplatin
7%
Dexamethasone
7%
Combination Therapy
7%
Bendamustine
7%
Mitoxantrone
7%
Cytarabine
7%
Fludarabine
7%
Clinical Trial
7%
Anthraquinone
7%
Lactate Dehydrogenase
6%
Population Study
6%
Disease
6%
Symptom
6%
Immunology and Microbiology
Dendritic Cell
100%
Vaccination Policy
56%
Bone Marrow Culture
56%
Mononuclear Cell
50%
Fetal Calf Serum
31%
C3H/He Mouse
25%
Monocyte
18%
Tumor Antigen
12%
Anaplastic Lymphoma Kinase
12%
Immune Response
12%
Mouse
12%
Tumor Cell
12%
Antigen
6%
Murine
6%
Peripheral Blood Mononuclear Cell
6%
T Cell
6%
Lymphoid Tissue
6%
Stem Cell
6%
Tumor Immunity
6%
Interleukin 4
6%
Cell Culture
6%
Granulocyte Macrophage Colony-Stimulating Factor
6%
Major Histocompatibility Complex
6%
CD86
6%
Mouse Model
6%
Mixed Lymphocyte Reaction
6%